Inmune Bio Inc. (INMB)
NASDAQ (CM) NASDAQ (CM) Primary Summary
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
Inmune Bio Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jeffery Yorg Focus Partners Advisor Solutions LLC | 43,025 | $117,495.46 | $88,416.37 | -$29,079.09 | -24.75% |
 Joseph Castro Nuveen LLC | 16,518 | $129,006 | $34,357.44 | -$94,648.56 | -73.37% |
 Bobby Adusumilli SJS Investment Consulting Inc. | 9 | $10.17 | $18.76 | $8.59 | 84.46% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $3.39 | $6.07 | $2.68 | 79.06% |
 Kevin Kroskey True Wealth Design LLC | 11 | $13 | $22.77 | $9.77 | 75.15% |
Inmune Bio Inc. (INMB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Inmune Bio Inc. ever had a stock split?
Inmune Bio Inc. Profile
| Biotechnology Industry | Healthcare Sector | David J. Moss CEO | NASDAQ (CM) Exchange | 45782T105 CUSIP |
| US Country | 21 Employees | - Last Dividend | - Last Split | 4 Feb 2019 IPO Date |
Overview
INmune Bio, Inc. is a clinical-stage immunology company based in the United States, dedicated to reprogramming the innate immune system to combat diseases. Established in 2015 and with its headquarters in Boca Raton, Florida, INmune Bio focuses on the development and commercialization of innovative therapeutic products aimed at the treatment of hematologic malignancies, solid tumors, and chronic inflammation. The company's approach involves leveraging the body's own immune system, aiming to offer novel treatments for patients with unmet medical needs. Through strategic license agreements with entities such as Xencor, Inc., Immune Ventures, LLC, and the University of Pittsburgh, INmune Bio is poised to advance its research and development initiatives in the field of immunotherapy.
Products and Services
- INKmune - Currently in Phase 1 clinical trials, INKmune is a promising therapy tailored for patients with high-risk myelodysplastic syndrome. This treatment is designed to enhance the patient's immune system to effectively identify and combat malignant cells.
- INB03 - INB03 is advancing through pre-clinical studies for its potential to counteract certain types of cancer that are resistant to conventional immunotherapies. Specifically, it is targeted towards cancers that express MUC4, a mucinous polyglucan that has been associated with resistance to immunotherapy treatments. This includes forms of HER2+ breast cancer and other cancers that express MUC4 and exhibit resistance to existing treatments.
- XPro1595 - XPro1595 represents INmune Bio's venture into the treatment of neuroinflammatory diseases, focusing on Alzheimer's disease and Treatment Resistant Depression (TRD). By targeting a novel aspect of the immune system related to inflammation, this drug candidate aims to provide relief and potentially modify the course of these debilitating conditions.
